Published: 28 June 2016
Author(s): Haralampos Milionis, Fotios Barkas, George Ntaios, Vasileios Papavasileiou, Kostantinos Vemmos, Patrick Michel, Moses Elisaf
Issue: June 2016
Section: Review Article

A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors alirocumab and evolocumab. We aimed to investigate the effect PCSK9 inhibition on stroke risk in a meta-analysis involving data from randomized studies with alirocumab and evolocumab.


Stay informed on our latest news!